Erythropoietin combined with liposomal amphotericin B improves outcome during disseminated aspergillosis in mice

Frontiers in Immunology

Volumn 5, Issue OCT, 2014, Pages

  Rousseau, Nathalie ^a   Picot, Stephane ^a,b   Bienvenu, Anne Lise ^a,b  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Adjuvant therapy; Amphotericin B; Erythropoietin; Invasive aspergillosis; Mortality; Murine model

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ERYTHROPOIETIN; GALACTOMANNAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLUS FUMIGATUS; BRAIN; CELL PROTECTION; CONTROLLED STUDY; FEMALE; HEART; INVASIVE ASPERGILLOSIS; LIVER; LONG TERM SURVIVAL; LUNG; MORTALITY; MOUSE; MURINAE; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84918797193     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00502     Document Type: Article

References (32)

1. Camargo JF, Husain S. Immune correlates of protection in human invasive aspergillosis. Clin Infect Dis (2014) 59:569-77. doi: 10.1093/cid/ciu337
2. Erjavec Z, Kluin-Nelemans H, Verweij PE. Trends in invasive fungal infections, with emphasis on invasive aspergillosis. Clin Microbiol Infect (2009) 15:625-33. doi:10.1111/j.1469-0691.2009.02929.x
3. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann J-W, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med (2002) 347:408-15. doi:10.1056/NEJMoa020191
4. Koulenti D, Garnacho-Montero J, Blot S. Approach to invasive pulmonary aspergillosis in critically ill patients. Curr Opin Infect Dis (2014) 27:174-83. doi:10.1097/QCO.0000000000000043
5. Gauwerky K, Borelli C, Korting HC. Targeting virulence: a new paradigm for antifungals. Drug Discov Today (2009) 14:214-22. doi:10.1016/j.drudis.2008.11.013
6. Kamai Y, Lossinsky AS, Liu H, Sheppard DC, Filler SG. Polarized response of endothelial cells to invasion by Aspergillus fumigatus. Cell Microbiol (2009) 11:170-82. doi:10.1111/j.1462-5822.2008.01247.x
7. Kamai Y, Chiang LY, Lopes Bezerra LM, Doedt T, Lossinsky AS, Sheppard DC, et al. Interactions of Aspergillus fumigatus with vascular endothelial cells. Med Mycol (2006) 44(Suppl 1):S115-7. doi:10.1080/13693780600897989
8. Ben-Ami R. Angiogenesis at the mold-host interface: a potential key to understanding and treating invasive aspergillosis. Future Microbiol (2013) 8:1453-62. doi:10.2217/fmb.13.114
9. Dagenais TRT, Keller NP. Pathogenesis of Aspergillus fumigatus in invasive aspergillosis. Clin Microbiol Rev (2009) 22:447-65. doi:10.1128/CMR.00055-08
10. Ghezzi P, Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ (2004) 11(Suppl 1):S37-44. doi:10.1038/sj.cdd.4401450
11. Broxmeyer HE. Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration. J Exp Med (2013) 210:205-8. doi:10.1084/jem.20122760
12. Hu R, Cheng Y, Jing H, Wu H. Erythropoietin promotes the protective properties of transplanted endothelial progenitor cells against acute lung injury via PI3K/Akt pathway. Shock (2014) 42(4):327-36. doi:10.1097/SHK.0000000000000216
13. Rodrigues CE, Sanches TR, Volpini RA, Shimizu MHM, Kuriki PS, Camara NOS, et al. Effects of continuous erythropoietin receptor activator in sepsis-induced acute kidney injury and multi-organ dysfunction. PLoS One (2012) 7:e29893. doi:10.1371/journal.pone.0029893
14. Eren Z, Coban J, Ekinci ID, Kaspar C, Kantarci G. Evaluation of the effects of a high dose of erythropoietin-beta on early endotoxemia using a rat model. Adv Clin Exp Med (2012) 21:321-9.
15. Dadimoghaddam Y, Daryani A, Sharif M, Ahmadpour E, Hossienikhah Z. Tissue tropism and parasite burden of Toxoplasma gondii RH strain in experimentally infected mice. Asian Pac J Trop Med (2014) 7:521-4. doi:10.1016/S1995-7645(14)60087-0
16. Yu JE, Kim M, Lee J-H, Chang B-J, Song C-S, Nahm S-S. Neonatal influenza infection causes pathological changes in the mouse brain. Vet Res (2014) 45:63. doi:10.1186/1297-9716-45-63
17. Saito TB, Thirumalapura NR, Shelite TR, Rockx-Brouwer D, Popov VL, Walker DH. An animal model of a newly emerging human ehrlichiosis. J Infect Dis (2014). doi:10.1093/infdis/jiu372
18. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis (2007) 44:1289-97. doi:10.1086/514341
19. Bienvenu A-L, Ferrandiz J, Kaiser K, Latour C, Picot S. Artesunate-erythropoietin combination for murine cerebral malaria treatment. Acta Trop (2008) 106:104-8. doi:10.1016/j.actatropica.2008.02.001
20. Bienvenu A-L, Picot S. Cerebral malaria: protection by erythropoietin. Methods Mol Biol (2013) 982:315-24. doi:10.1007/978-1-62703-308-4_19
21. Picot S, Bienvenu A-L, Konate S, Sissoko S, Barry A, Diarra E, et al. Safety of epoietin beta-quinine drug combination in children with cerebral malaria in Mali. Malar J (2009) 8:169. doi:10.1186/1475-2875-8-169
22. Gorelik O, Cohen N, Shpirer I, Almoznino-Sarafian D, Alon I, Koopfer M, et al. Fatal haemoptysis induced by invasive pulmonary aspergillosis in patients with acute leukaemia during bone marrow and clinical remission: report of two cases and review of the literature. J Infect (2000) 41:277-82. doi:10.1053/jinf.2000.0744
23. Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med (2008) 264:405-32. doi:10.1111/j.1365-2796.2008.02024.x
24. Dockrell DH. Salvage therapy for invasive aspergillosis. J Antimicrob Chemother (2008) 61(Suppl 1):i41-4. doi:10.1093/jac/dkm426
25. Craig AG, Grau GE, Janse C, Kazura JW, Milner D, Barnwell JW, et al. Participants of the Hinxton retreat meeting on animal models for research on severe malaria. The role of animal models for research on severe malaria. PLoS Pathog (2012) 8:e1002401. doi:10.1371/journal.ppat.1002401
26. Paulussen C, Boulet GAV, Cos P, Delputte P, Maes LJRM. Animal models of invasive aspergillosis for drug discovery. Drug Discov Today (2014) 19(9):1380-86. doi:10.1016/j.drudis.2014.06.006
27. Xu P, Qu J-M, Xu J-F, Zhang J, Jiang H-N, Zhang H-J. NAC is associated with additional alleviation of lung injury induced by invasive pulmonary aspergillosis in a neutropenic model. Acta Pharmacol Sin (2009) 30:980-6. doi:10.1038/aps.2009.83
28. Chu H, Ding H, Tang Y, Dong Q. Erythropoietin protects against hemorrhagic blood-brain barrier disruption through the effects of aquaporin-4. Lab Invest (2014) 94(9):1042-53. doi:10.1038/labinvest.2014.84
29. Aapro M, Osterwalder B, Scherhag A, Burger HU. Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events. Br J Cancer (2009) 101:1961-71. doi:10.1038/sj.bjc.6605255
30. Henke M, Laszig R, Rübe C, Schäfer U, Haase K-D, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet (2003) 362:1255-60. doi:10.1016/S0140-6736(03)14567-9
31. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med (1998) 339:584-90. doi:10.1056/NEJM199808273390903
32. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med (2002) 8:495-505.